Blood pressure decrease in spontaneously hypertensive rats folowing renal denervation or dopamine β-hydroxylase inhibition with etamicastat

Hypertension Research

Volumn 38, Issue 9, 2015, Pages 605-612

  Pires, Nuno Miguel ^a   Igreja, Bruno ^a   Moura, Eduardo ^a   Wright, Lyndon Christopher ^a   Serrão, Maria Paula ^b,c   Soares da Silva, Patrício ^a,b,c  

^a DEPARTMENT OF RESEARCH AND DEVELOPMENT   (Portugal)

^b University of Porto   (Portugal)

^c UNIVERSITY OF PORTO   (Portugal)

Author keywords

dopamine hydroxylase inhibition; renal denervation; spontaneously hypertensive rat; sympathetic nervous system

Indexed keywords

CARPROFEN; DOPAMINE; DOPAMINE BETA MONOOXYGENASE; ELECTROLYTE; ETAMICASTAT; NORADRENALIN; BENZOPYRAN DERIVATIVE; ENZYME INHIBITOR; IMIDAZOLE DERIVATIVE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIHYPERTENSIVE ACTIVITY; ANTIHYPERTENSIVE THERAPY; ARTICLE; CARDIOVASCULAR RESPONSE; COHORT ANALYSIS; CONTROLLED STUDY; DIASTOLIC BLOOD PRESSURE; DOWN REGULATION; DRUG EFFICACY; ELECTROLYTE URINE LEVEL; EXPERIMENTAL HYPERTENSION; FLUID BALANCE; HEART LEFT VENTRICLE; INTERVENTION STUDY; KIDNEY DENERVATION; KIDNEY FUNCTION; KIDNEY PARENCHYMA; MALE; NONHUMAN; NORMAL VALUE; RAT; SPONTANEOUSLY HYPERTENSIVE RAT; SYSTOLIC BLOOD PRESSURE; ANIMAL; ANTAGONISTS AND INHIBITORS; BLOOD PRESSURE; DENERVATION; DRUG EFFECTS; ELECTROLYTE BALANCE; HEMODYNAMICS; INNERVATION; KIDNEY; METABOLISM;

ANIMALS; BENZOPYRANS; BLOOD PRESSURE; DENERVATION; DOPAMINE; DOPAMINE BETA-HYDROXYLASE; ENZYME INHIBITORS; HEMODYNAMICS; IMIDAZOLES; KIDNEY; MALE; NOREPINEPHRINE; RATS; RATS, INBRED SHR; WATER-ELECTROLYTE BALANCE;

EID: 84941123023     PISSN: 09169636     EISSN: 13484214     Source Type: Journal    
DOI: 10.1038/hr.2015.50     Document Type: Article

References (60)

1. Mancia G, Fagard R, Narkiewicz K, Redon J, Zanchetti A, Bohm M, Christiaens T, Cifkova R, De Backer G, Dominiczak A, Galderisi M, Grobbee DE, Jaarsma T, Kirchhof P, Kjeldsen SE, Laurent S, Manolis AJ, Nilsson PM, Ruilope LM, Schmieder RE, Sirnes PA, Sleight P, Viigimaa M, Waeber B, Zannad F, Burnier M, Ambrosioni E, Caufield M, Coca A, Olsen MH, Tsioufis C, van de Borne P, Zamorano JL, Achenbach S, Baumgartner H, Bax JJ, Bueno H, Dean V, Deaton C, Erol C, Ferrari R, Hasdai D, Hoes AW, Knuuti J, Kolh P, Lancellotti P, Linhart A, Nihoyannopoulos P, Piepoli MF, Ponikowski P, Tamargo JL, Tendera M, Torbicki A, Wijns W, Windecker S, Clement DL, Gillebert TC, Rosei EA, Anker SD, Bauersachs J, Hitij JB, Caulfield M, De Buyzere M, De Geest S, Derumeaux GA, Erdine S, Farsang C, Funck-Brentano C, Gerc V, Germano G, Gielen S, Haller H, Jordan J, Kahan T, Komajda M, Lovic D, Mahrholdt H, Ostergren J, Parati G, Perk J, Polonia J, Popescu BA, Reiner Z, Ryden L, Sirenko Y, Stanton A, Struijker-Boudier H, Vlachopoulos C, Volpe M, Wood DA2013ESH/ESC Guidelines for the management of arterial hypertension: The Task Force for the management of arterial hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC). Eur Heart J 2013; 34: 2159-2219.
2. Kearney PM, Whelton M, Reynolds K, Muntner P, Whelton PK, He J. Global burden of hypertension: analysis of worldwide data. Lancet 2005; 365: 217-223.
3. Nishikawa T, Omura M, Saito J, Matsuzawa Y. The possibility of resistant hypertension during the treatment of hypertensive patients. Hypertens Res 2013; 36: 924-929.
4. Calhoun DA, Jones D, Textor S, Goff DC, Murphy TP, Toto RD, White A, Cushman WC, White W, Sica D, Ferdinand K, Giles TD, Falkner B, Carey RM. Resistant hypertension: diagnosis, evaluation, and treatment. A scientific statement from the American Heart Association Professional Education Committee of the Council for High Blood Pressure Research. Hypertension 2008; 51: 1403-1419.
5. Grassi G. Sympathetic neural activity in hypertension and related diseases. Am J Hypertens 2010; 23: 1052-1060.
6. Grassi G, Seravalle G, Quarti-Trevano F. The 'neuroadrenergic hypothesis' in hypertension: current evidence. Exp Physiol 2010; 95: 581-586.
7. Esler M, Kaye D. Sympathetic nervous system activation in essential hypertension, cardiac failure and psychosomatic heart disease. J Cardiovasc Pharmacol 2000; 35: S1-S7.
8. Parati G, Esler M. The human sympathetic nervous system: its relevance in hypertension and heart failure. Eur Heart J 2012; 33: 1058-1066.
9. Grassi G, Bolla G, Quarti-Trevano F, Arenare F, Brambilla G, Mancia G. Sympathetic activation in congestive heart failure: reproducibility of neuroadrenergic markers. Eur J Heart Fail 2008; 10: 1186-1191.
10. Lee CS, Tkacs NC. Current concepts of neurohormonal activation in heart failure: mediators and mechanisms. AACN Adv Crit Care 2008; 19: 364-385.
11. Mancia G, Grassi G, Giannattasio C, Seravalle G. Sympathetic activation in the pathogenesis of hypertension and progression of organ damage. Hypertension 1999; 34: 724-728.
12. Malpas SC. Sympathetic nervous system overactivity and its role in the development of cardiovascular disease. Physiol Rev 2010; 90: 513-557.
13. Krum H, Schlaich M, Whitbourn R, Sobotka PA, Sadowski J, Bartus K, Kapelak B, Walton A, Sievert H, Thambar S, Abraham WT, Esler M. Catheter-based renal sympathetic denervation for resistant hypertension: a multicentre safety and proof-ofprinciple cohort study. Lancet 2009; 373: 1275-1281.
14. Worthley SG, Tsioufis CP, Worthley MI, Sinhal A, Chew DP, Meredith IT, Malaiapan Y, Papademetriou V. Safety and efficacy of a multi-electrode renal sympathetic denervation system in resistant hypertension: the EnligHTN I trial. Eur Heart J 2013; 34: 2132-2140.
15. Cohen-Mazor M, Mathur P, Stanley JR, Mendelsohn FO, Lee H, Baird R, Zani BG, Markham PM, Rocha-Singh K. Evaluation of renal nerve morphological changes and norepinephrine levels following treatment with novel bipolar radiofrequency delivery systems in a porcine model. J Hypertens 2014; 32: 1678-1691.
16. Mabin T, Sapoval M, Cabane V, Stemmett J, Iyer M. First experience with endovascular ultrasound renal denervation for the treatment of resistant hypertension. EuroIntervention 2012; 8: 57-61.
17. Ormiston JA, Watson T, van Pelt N, Stewart R, Haworth P, Stewart JT, Webster MW. First-in-human use of the OneShot? renal denervation system from Covidien. Euro- Intervention 2013; 8: 1090-1094.
18. Mahfoud F, Luscher TF, Andersson B, Baumgartner I, Cifkova R, Dimario C, Doevendans P, Fagard R, Fajadet J, Komajda M, Lefevre T, Lotan C, Sievert H, Volpe M, Widimsky P, Wijns W, Williams B, Windecker S, Witkowski A, Zeller T, Bohm M. Expert consensus document from the European Society of Cardiology on catheter-based renal denervation. Eur Heart J 2013; 34: 2149-2157.
19. Esler MD, Bohm M, Sievert H, Rump CL, Schmieder RE, Krum H, Mahfoud F, Schlaich MP. Catheter-based renal denervation for treatment of patients with treatmentresistant hypertension: 36 month results from the SYMPLICITY HTN-2 randomized clinical trial. Eur Heart J 2014; 35: 1752-1759.
20. Bhatt DL, Kandzari DE, O'Neill WW, D'Agostino R, Flack JM, Katzen BT, Leon MB, Liu M, Mauri L, Negoita M, Cohen SA, Oparil S, Rocha-Singh K, Townsend RR, Bakris GL. A controlled trial of renal denervation for resistant hypertension. N Engl J Med 2014; 370: 1393-1401.
21. Hayek SS, Abdou MH, Demoss BD, Legaspi JM, Veledar E, Deka A, Krishnan SK, Wilmot KA, Patel AD, Kumar VR, Devireddy CM. Prevalence of resistant hypertension and eligibility for catheter-based renal denervation in hypertensive outpatients. Am J Hypertens 2013; 26: 1452-1458.
22. Stanley WC, Li B, Bonhaus DW, Johnson LG, Lee K, Porter S, Walker K, Martinez G, Eglen RM, Whiting RL, Hegde SS. Catecholamine modulatory effects of nepicastat (RS-25560-197), a novel, potent and selective inhibitor of dopamine-beta-hydroxylase. Br J Pharmacol 1997; 121: 1803-1809.
23. Hegde SS, Friday KF. Dopamine-beta-hydroxylase inhibition: a novel sympathomodulatory approach for the treatment of congestive heart failure. Curr Pharm Des 1998; 4: 469-479.
24. Soares-da-Silva P. Evidence for a non-precursor dopamine pool in noradrenergic neurones of the dog mesenteric artery. Naunyn Schmiedebergs Arch Pharmacol 1986; 333: 219-223.
25. Soares-da-Silva P. A comparison between the pattern of dopamine and noradrenaline release from sympathetic neurones of the dog mesenteric artery. Br J Pharmacol 1987; 90: 91-98.
26. Gomes P, Soares-da-Silva P. Dopamine. In: Baden M (ed), Cardiovascular Hormone Systems: From Molecular Mechanisms to Novel Therapeutics. Wiley-VCH: Weinheim. 2008, 251-293.
27. Jose PA, Eisner GM, Felder RA. Role of dopamine receptors in the kidney in the regulation of blood pressure. Curr Opin Nephrol Hypertens 2002; 11: 87-92.
28. Jose PA, Soares-da-Silva P, Eisner GM, Felder RA. Dopamine and G protein-coupled receptor kinase 4 in the kidney: role in blood pressure regulation. Biochim Biophys Acta 2010; 1802: 1259-1267.
29. Ishii Y, Fujii Y, Mimura C, Umezawa H. Pharmacological action of FD-008, a new dopamine beta-hydroxylase inhibitor. I. Effects on blood pressure in rats and dogs. Arzneimittelforschung 1975; 25: 55-59.
30. Kruse LI, Kaiser C, DeWolf WE Jr., Frazee JS, Ross ST, Wawro J, Wise M, Flaim KE, Sawyer JL, Erickson RW, Ezekiel M, Ohlstein EH, Berkowitz BA. Multisubstrate inhibitors of dopamine beta-hydroxylase. 2. Structure-activity relationships at the phenethylamine binding site. J Med Chem 1987; 30: 486-494.
31. Ohlstein EH, Kruse LI, Ezekiel M, Sherman SS, Erickson R, DeWolf WE Jr, Berkowitz BA. Cardiovascular effects of a new potent dopamine beta-hydroxylase inhibitor in spontaneously hypertensive rats. J Pharmacol Exp Ther 1987; 241: 554-559.
32. Beliaev A, Ferreira H, Learmonth DL, Soares-da-Silva P. Dopamine beta-monooxygenase: mechanism, substrates and inhibitors. Curr Enzyme Inh 2009; 5: 27-43.
33. Kruse LI, Kaiser C, DeWolf WE Jr., Frazee JS, Erickson RW, Ezekiel M, Ohlstein EH, Ruffolo RR Jr, Berkowitz BA. Substituted 1-benzylimidazole-2-thiols as potent and orally active inhibitors of dopamine beta-hydroxylase. J Med Chem 1986; 29: 887-889.
34. Beliaev A, Learmonth DA, Soares-da-Silva P. Synthesis and biological evaluation of novel, peripherally selective chromanyl imidazolethione-based inhibitors of dopamine beta-hydroxylase. J Med Chem 2006; 49: 1191-1197.
35. Bonifácio MJ, Igreja B, Wright L, Soares-da-Silva P. Kinetic studies on the inhibition of dopamine-ß-hydroxylase by BIA 5-453. PA2 online 2009; 7: 050P.
36. Igreja B, Pires NM, Bonifácio MJ, Loureiro AI, Fernandes-Lopes C, Wright LC, Soaresda- Silva P. Blood pressure-decreasing effect of etamicastat alone and in combination with antihypertensive drugs in the spontaneously hypertensive rat. Hypertens Res 2015; 38: 30-38.
37. Igreja B, Wright L, Soares-da-Silva P. Sustained antihypertensive effects of a selective peripheral dopamine-ß-hydroxylase inhibitor. Hypertension 2007; 50: E133.
38. Almeida L, Nunes T, Costa R, Rocha JF, Vaz-da-Silva M, Soares-da-Silva P. Etamicastat, a novel dopamine beta-hydroxylase inhibitor: tolerability, pharmacokinetics, and pharmacodynamics in patients with hypertension. Clin Ther 2013; 35: 1983-1996.
39. Jacob F, Ariza P, Osborn JW. Renal denervation chronically lowers arterial pressure independent of dietary sodium intake in normal rats. Am J Physiol Heart Circ Physiol 2003; 284: H2302-H2310.
40. Loureiro AI, Fernandes-Lopes C, Bonifacio MJ, Wright LC, Soares-da-Silva P. Nacetylation of etamicastat, a reversible dopamine-beta-hydroxylase inhibitor. Drug Metab Dispos 2013; 41: 2081-2086.
41. Soares-da-Silva P, Pestana M, Vieira-Coelho MA, Fernandes MH, Albino-Teixeira A. Assessment of renal dopaminergic system activity in the nitric oxide-deprived hypertensive rat model. Br J Pharmacol 1995; 114: 1403-1413.
42. Nagatsu T, Udenfriend S. Photometric assay of dopamine-beta-hydroxylase activity in human blood. Clin Chem 1972; 18: 980-983.
43. Rocha JF, Vaz-da-Silva M, Nunes T, Igreja B, Loureiro AI, Bonifácio MJ, Wright LC, Falcão A, Almeida L, Soares-da-Silva P. Single-dose tolerability, pharmacokinetics, and pharmacodynamics of etamicastat (BIA 5-453), a new dopamine ß-hydroxylase inhibitor, in healthy subjects. J Clin Pharmacol 2012; 52: 156-170.
44. Papademetriou V, Tsioufis CP, Sinhal A, Chew DP, Meredith IT, Malaiapan Y, Worthley MI, Worthley SG. Catheter-based renal denervation for resistant hypertension: 12-month results of the EnligHTN I first-in-human study using a multielectrode ablation system. Hypertension 2014; 64: 565-572.
45. Jose PA, Eisner GM, Drago J, Carey RM, Felder RA. Dopamine receptor signaling defects in spontaneous hypertension. Am J Hypertens 1996; 9: 400-405.
46. Doggrell SA, Brown L. Rat models of hypertension, cardiac hypertrophy and failure. Cardiovasc Res 1998; 39: 89-105.
47. Du CQ, Yang L, Yang J, Han J, Hu XS, Wu T, Hu SJ. Inhibition of farnesyl pyrophosphate synthase prevents norepinephrine-induced fibrotic responses in vascular smooth muscle cells from spontaneously hypertensive rats. Hypertens Res 2014; 37: 26-34.
48. Winternitz SR, Katholi RE, Oparil S. Role of the renal sympathetic nerves in the development and maintenance of hypertension in the spontaneously hypertensive rat. J Clin Invest 1980; 66: 971-978.
49. Jiang W, Tan L, Guo Y, Li X, Tang X, Yang K. Effect of renal denervation procedure on left ventricular hypertrophy of hypertensive rats and its mechanisms. Acta Cir Bras 2012; 27: 815-820.
50. Kline RL, Stuart PJ, Mercer PF. Effect of renal denervation on arterial pressure and renal norepinephrine concentration in Wistar-Kyoto and spontaneously hypertensive rats. Can J Physiol Pharmacol 1980; 58: 1384-1388.
51. Foss JD, Fink GD, Osborn JW. Reversal of genetic salt-sensitive hypertension by targeted sympathetic ablation. Hypertension 2013; 61: 806-811.
52. Guyton AC. Blood pressure control-special role of the kidneys and body fluids. Science 1991; 252: 1813-1816.
53. Nadeau RA, de Champlain J, Tremblay GM. Supersensitivity of the isolated rat heart after chemical sympathectomy with 6-hydroxydopamine. Can J Physiol Pharmacol 1971; 49: 36-44.
54. Kline RL, Mercer PF. Functional reinnervation and development of supersensitivity to NE after renal denervation in rats. Am J Physiol 1980; 238: R353-R358.
55. Krayacich J, Kline RL, Mercer PF. Supersensitivity to NE alters renal function of chronically denervated rat kidneys. Am J Physiol 1987; 252: F856-F864.
56. Overy HR, Pfister R, Chidsey CA. Studies on the renal excretion of norepinephrine. J Clin Invest 1967; 46: 482-489.
57. Eisenhofer G, Kopin IJ, Goldstein DS. Catecholamine metabolism: a contemporary view with implications for physiology and medicine. Pharmacol Rev 2004; 56: 331-349.
58. Roberts NB, Dutton J, McClelland P, Bone JM. Urinary catecholamine excretion in relation to renal function. Ann Clin Biochem 1999; 36: 587-591.
59. Silva P, Landsberg L, Besarab A. Excretion and metabolism of catecholamines by the isolated perfused rat kidney. J Clin Invest 1979; 64: 850-857.
60. Rosendorff C, Black HR, Cannon CP, Gersh BJ, Gore J, Izzo JLJ, Kaplan NM, O'Connor CM, O'Gara PT, Oparil S. Treatment of hypertension in the prevention and management of ischemic heart disease: a scientific statement from the American Heart Association Council for High Blood Pressure Research and the Councils on Clinical Cardiology and Epidemiology and Prevention. Circulation 2007; 115: 2761-2788.